410 related articles for article (PubMed ID: 29885023)
21. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
[TBL] [Abstract][Full Text] [Related]
22. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
24. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
25. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
[TBL] [Abstract][Full Text] [Related]
26. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J
Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
28. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Jin J; Liu BZ; Wu ZM
J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Tominaga T; Tsuchiya T; Mochinaga K; Arai J; Yamasaki N; Matsumoto K; Miyazaki T; Nagasaki T; Nanashima A; Tsukamoto K; Nagayasu T
BMC Cancer; 2016 Jun; 16():354. PubMed ID: 27268079
[TBL] [Abstract][Full Text] [Related]
32. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
[TBL] [Abstract][Full Text] [Related]
34. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
35. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Wang XJ; Zhou RJ; Zhang N; Jing Z
Eur J Pharmacol; 2019 May; 850():141-149. PubMed ID: 30772396
[TBL] [Abstract][Full Text] [Related]
36. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
37. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
38. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
39. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
[TBL] [Abstract][Full Text] [Related]
40. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Tan F; Shen X; Wang D; Xie G; Zhang X; Ding L; Hu Y; He W; Wang Y; Wang Y
Lung Cancer; 2012 May; 76(2):177-82. PubMed ID: 22112293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]